Perioperative IV Antihypertensive Agents Cheat Sheet    body {font-family: 'Open Sans', sans-serif;}

### Perioperative IV Antihypertensive Agents Cheat Sheet

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Esmolol (Brevibloc) IV |
| --- |
| Selective B1 antagonist  
**Bolus:** 0.5 -1 mg/kg  
**Loading dose:** 0.5 mg/kg then  
**Infusion:** 25-300 mcg/kg/min  
**Onset:** 1-2 minutes  
**Plasma ½ life:** 9 minutes  
**Duration of clinical effect:** 10-30 minutes  
  
**Notes:**  
100-200 mg IV two mins before direct laryngoscopy or before induction to prevent  
hypertension and tachycardia for vascular or cardiac patients with a higher risk  
of perioperative MACE.  
**MACE:** Major adverse cardiac events |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Metoprolol (Lopressor) IV |
| --- |
| Selective B1 antagonist  
**Bolus:** 1-5 mg  
**Infusion:** N/A  
**Onset:** 1-5 minutes  
**Plasma ½ life:** 3-4 hours  
**Duration of clinical effect:** 1-4 hours  
  
**Notes:**  
The common beta-blocker administered pre-op or preinduction for cardiac  
patients with a higher risk of perioperative MACE.  
**MACE:** Major adverse cardiac events |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Labetalol (Trandate) IV |
| --- |
| Selective A1 and Nonselective B1, B2 antagonist. Beta to alpha potency ratio: 7:1 (IV).  
**Bolus:** 5-20 mg  
**Infusion:** 0.5-2 mg/min (30-120 mg/hr)  
**Onset:** 1-5 minutes  
**Plasma ½ life:** 4-8 hours  
**Duration of clinical effect:** 1-4 hours  
  
**Notes:**  
May repeat doses of 20-80 mg IV Q 10 minutes until desired BP is achieved.  
Caution with COPD due to B2 antagonism.  
_However, reported perioperative bronchospasms in COPD patients following labetalol are extremely rare._ |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Cardene (Nicardipine) IV |
| --- |
| Dihydropyridine Ca channel blocker  
Selective arteriolar dilator  
**Bolus:** 0.1-0.4 mg  
**Infusion:** 5-15 mg/hour  
**Onset:** 2-10 minutes  
**Plasma ½ life:** 2-4 hours  
**Duration of clinical effect:** 30-60 minutes  
  
**Notes:**  
Popular for preventing/treating post-op HTN for vascular procedures.  
↑ relaxation to coronary and cerebrovascular beds.  
↓SVR, systolic BP and MAP  
↑CO, stroke volume and LVEF  
↓ or no change in LVEDP  
Slight ↑ HR from baroreceptor reflex  
  
**Concentrations:**  
0.1 mg/mL or 0.2 mg/mL  
0.5 mg/mL for fluid restricted patients |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Clevidipine (Cleviprex) IV |
| --- |
| Dihydropyridine Ca channel blocker  
Selective arteriolar dilator  
**Bolus:** 1-2 mg/hr  
**Infusion:** 1-16 mg/hr (↑1-2 mg/hr will ↓ SBP by 2-4 mmHg)  
**Onset:** 1-4 minutes  
**Plasma ½ life:** 1 minute  
**Duration of clinical effect:** 5-15 minutes  
  
**Notes:**  
↓ SVR w/o affecting preload  
↑CO, stroke volume and LVEF  
Has an ultra-faster onset and offset  
Replacing Nitroprusside  
Contains 0.2 grams of lipids/mL  
Looks like propofol  
Metabolized rapidly by plasma esterases and not affected by renal or hepatic dysfunction.  
  
**Contraindicated:**  
When allergic to soybeans, soy products, eggs, or egg products.  
Patient with defective lipid metabolism |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Fenoldopam (Corlapam) IV |
| --- |
| Dopamine-1 (D1) receptor agonist  
Arteriolar dilator  
**Bolus:** N/A  
**Infusion:** 0.05-1.6 mcg/kg/min  
**Onset:** 5-10 minutes  
**Plasma ½ life:** 5 minutes  
**Duration of clinical effect:** 30-60 minutes  
  
**Notes:**  
Increases renal blood flow and urine output while decreasing BP.  
Beneficial with chronic kidney disease.  
Slight ↑ HR from baroreceptor reflex. |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Hydralazine (Apresoline) IV |
| --- |
| Arteriolar dilation  
**Bolus:** 5-20 mg  
**Initial infusion:** 200-300 mcg/min  
**Maintenance:** 50-150mcg/min  
**Onset:** 1-5 minutes  
**Plasma ½ life:** 2-8 hours  
**Duration of clinical effect:** 1-8 hours  
  
**Notes:** May repeat in intervals of 20-30 minutes.  
Rare for continuous infusion.  
Preferred over a beta-blocker when the patient's HR is slow. |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Nipride (Nitroprusside) IV |
| --- |
| Nitric oxide donor  
Arteriolar and venovasodilator  
**Bolus:** 40 mcg  
**Infusion:** 0.25-10 mcg/kg/min  
**Onset:** Immediate  
**Plasma ½ life:** < 10 mins  
**Duration of clinical effect:** 5-10 mins  
  
**Notes:**  
↓ SVR, ventricular filling pressures, and systemic BP.  
↑ CO  
  
**Mix:** 50 mg in 250 mL = 200 mcg/mL or 100 mg in 250 mL = 400 mcg/mL  
Commonly mixed with NS or D5W  
Emergency syringe: Mix 1 mL (200 mcg) with 4 mL of NS = 40 mcg/mL  
Not as common anymore due to the risk of cyanide toxicity and newer, fast acting antihypertensive meds. |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Nitroglycerine (Tridil) IV |
| --- |
| Nitric oxide donor  
**Bolus:** 20-40 mcg  
**Infusion:** 0.25-10 mcg/kg/min or 10-400 mcg/min  
**Onset:** 1-2 minutes  
**Plasma ½ life:** 1-3 minutes  
**Duration of clinical effect:** 5-10 minutes  
  
**Notes:**  
Many anesthesia providers will manually titrate to effect intraoperatively (not using a pump) with BP swings in vascular and cardiac cases. |

  
table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Phentolamine Mesylate (Regitine) IV |
| --- |
| Nonselective antagonist to postsynaptic Alpha 1 and presynaptic Alpha 2 receptors  
**Bolus:** 1-5 mg IV as needed (usually 5 mg), Peds: 1 mg bolus  
**Infusion:** Rare (Intraoperative continuous infusions are rare) 6-60 mg/hour or 0.5-1 mg/min) and titrate to affect. Literature varies  
**Onset:** 1-2 minutes  
**Plasma ½ life:** 10-20 minutes  
**Duration of clinical effect:** 5-30 minutes  
  
**Also used for IV extravasation:**  
5-10 mg diluted in10 mLs of NS and inject into the affected tissue site (SQ).  
  
**Notes:**  
Used by anesthesia providers intraoperatively for the treatment of a hypertensive crisis from the surgical manipulation of a pheochromocytoma.  
Also used for treating the tissue site of IV extravasation from vasoconstricting agents to prevent necrosis.  
Some surgical pharmacies no longer carry phentolamine. |

  
  

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6 th Ed. 2022, CH 20  
Pamela Flood and James P. Rathmell  
  
Morgan & Mikhail’s Clinical Anesthesiology 7 th Ed. 2022,  
John F. Butterworth, David C. Mackey and John D. Wasnick~  
Kaplan’s Essentials of Cardiac Anesthesia for Cardiac Surgery 2 nd Ed. 2018; pages 250-266  
Joe A. Kaplan, MD, Brett Cronin, MD, and Timothy Maus MD  
  
Kaplan’s Essentials of Cardiac Anesthesia for Noncardiac Surgery 2019  
Joe A. Kaplan, MD, Brett Cronin, MD, and Timothy Maus MD  
  
Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion  
EMC (accessed 09/2022)  
https://www.medicines.org.uk/emc/product/6710/smpc#gref  
  
Cleviprex (clevidipine) Pharmacology and Mechanism of Action  
https://cleviprex.com/pharmacology-moa/  
  
Cleviprex (clevidipine)  
FDA Draft Labeling (accessed 09/2022)  
https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/022156s003lbl.pdf  
  
Phentolamine Mesylate  
FDA Package insert (accessed 09/2022)  
https://www.accessdata.fda.gov/drugsatfda\_docs/anda/98/40235ap.pdf  
Cardene  
FDA Reference ID: 2901740 (accessed 09/2022)  
https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/019734s017lbl.pdf  
  
Sodium Nitroprusside  
StatPearls (accessed 09/2022)  
Matthew R. Holme; Tariq Sharman  
https://www.ncbi.nlm.nih.gov/books/NBK557487/  
  
Fenoldopam  
National Library of Medicine  
StatPearls (accessed 09/2022)  
Michael W. Szymanski; John R. Richards.  
https://www.ncbi.nlm.nih.gov/books/NBK526058/  
  
Phentolamine continuous infusion in a patient with pheochromocytoma  
Gale Academic ONEFile (accessed 09/2022)  
Wesley D. McMillian, Bryan J Trombley  
https://tinyurl.com/cpvttjxd  
  
Phentolamine Mesylate for Injection USP  
Center for Drug Evaluation and Research (accessed 09/2022)  
https://www.accessdata.fda.gov/drugsatfda\_docs/anda/98/40235ap.pdf